US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction

/PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg to reduce the risk of cardiovascular death and...

Related Keywords

New York ,United States ,Stephan Thalen ,Mohamed Eid ,Javed Butler ,Eli Lilly ,Michele Baer ,Jeff Emmick ,Global Business Communications ,Boehringer Ingelheim Pharmaceuticals Inc ,Twitter ,Clinical Development Medical Affairs ,Boehringer Ingelheim ,Boehringer Ingelheim Animal Health In Duluth ,Lilly United States ,Product Development ,University Of Mississippi ,Facebook ,Department Of Medicine ,Drug Administration ,European Commission ,Lilly Alliance ,Exchange Commission ,Boehringer Ingelheim Corporation ,Animal Health ,Boehringer Ingelheim Fremont Inc ,Important Safety Information ,Clinical Development ,Medical Affairs ,Respiratory Medicine ,Boehringer Ingelheim Pharmaceuticals ,New York Heart ,Prescribing Information ,Human Pharma ,Biopharmaceutical Contract ,Ingelheim Pharmaceuticals ,Boehringer Ingelheim Animal Health ,Boehringer Ingelheim Fremont ,Corporate Social Responsibility ,Private Securities Litigation Reform Act ,Current State ,Eli Lilly And Company ,